<DOC>
	<DOCNO>NCT01179646</DOCNO>
	<brief_summary>The objective study determine single-dose bioequivalence test product , potential generic 40 mg pantoprazole delayed-release tablet formulation , compare reference product , pantoprazole 40 mg delayed-release tablet formulation ( Protonix , Wyeth Pharmaceuticals ) , follow single dose fast state .</brief_summary>
	<brief_title>Bioequivalence Study Pantoprazole 40 mg DR Tablets Protonix 40 mg Tablets</brief_title>
	<detailed_description>The 90 % CI pantoprazole ln ( Cmax ) , ln [ AUC ( 0-t ) ] , ln [ AUC ( 0-inf ) ] comparison test product ( pantoprazole ) versus reference product ( Protonix ) within 80 125 % range require conclusion bioequivalence .</detailed_description>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Non tobacco/nicotineusing ( 6 month minimum ) healthy male females 19 50 year age . Body weight 15 % 15 % , inclusive , ideal weight height estimate frame , adapted 1983 Metropolitan Life Table . Female subject surgically sterile , least two year postmenopausal , sexually active , partner vasectomize least 6 month , agree utilize one follow form contraception : barrier ( condom spermicide diaphragm spermicide ) , IUD , hormonal ( oral , implant , transdermal patch , injection ) follow specify time . Subjects use hormonal contraceptive stable dose 3 month prior dose , agree also use barrier method birth control screen completion study . Subjects intrauterine device ( IUD ) must IUD place least 2 month prior dose , agree also use barrier method birth control screen completion study . For form birth control , subject use method least 2 week prior screen agree use method completion study . Voluntary consent participate study demonstrate sign informed consent form . Persons Asian origin . Females pregnant lactating . History clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric , cardiovascular disease , condition , opinion Investigator , could jeopardize safety subject impact validity study result . History hypersensitivity , allergic adverse response pantoprazole relate drug . Positive result HIV antibody screen , hepatitis B surface antigen screen , and/or hepatitis C antibody screen . Participation previous clinical trial within 30 day prior study initiation . Donation one pint whole blood within 56 day prior study initiation . Donation 2 unit red blood cell within 112 day prior study initiation . Donation plasma 7 day prior study initiation . Difficulty swallow medication gastrointestinal disease could affect drug absorption . Abnormal diet substantial change eat habit within 30 day prior study initiation . Examples include , limit , vegetarian , fasting , liquid supplement , etc . Treatment known enzymealtering agent ( barbiturate , phenothiazine , cimetidine , etc . ) within 30 day prior study initiation . Use prescription medication ( except hormonal contraceptive female ) within 14 day prior study initiation . Use overthecounter ( OTC ) medication , include megadose vitamin , analgesic , herbal/nutritional supplement , antacid , within 7 day prior study initiation . Positive urine screen alcohol drug abuse . Unwilling eat food provide study menu . Hemoglobin &lt; 12.0 g/dL . History alcohol drug abuse within 2 year prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalency</keyword>
</DOC>